Core Insights - Omvoh (mirikizumab) is the first and only IL-23p19 antagonist demonstrating sustained long-term efficacy in patients with moderately to severely active ulcerative colitis (UC) over four years [1][5][19] Group 1: Clinical Efficacy - Approximately 80% of patients treated with Omvoh in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission [1] - At four years, nearly all patients who achieved clinical remission at one year reported improvements in bowel urgency, a significant symptom for patients [1] - Key efficacy results after four years include: - 78% achieved corticosteroid-free clinical remission - 78% sustained long-term clinical remission - 81% sustained endoscopic remission - 90% achieved remission on the Inflammatory Bowel Disease Questionnaire (IBDQ) - 66% achieved histological-endoscopic mucosal improvement - 93% achieved a 3 or more-point reduction on the Urgency Numeric Rating Scale (UNRS) [6][9] Group 2: Safety Profile - The long-term safety profile of Omvoh in patients with moderately to severely active UC was consistent with its known safety profile, with no new safety signals observed [4] - Among patients who completed one year of blinded Omvoh maintenance therapy, 12% reported a serious adverse event, while 7% discontinued treatment due to an adverse event [4] Group 3: Future Developments - Lilly is advancing combination studies of mirikizumab aimed at enhancing induction efficacy while maintaining long-term remission and safety [5] - Ongoing studies include trials evaluating the concomitant use of mirikizumab with incretin-based therapies [7]